Scholars Central

Conference abstractPublished 29 Sep 2014

Characterization of inflammation and immune cell modulation induced by low-dose LPS administration to healthy volunteers

Authors: Marlous Dillingh

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Human in vivo models of systemic inflammation are used to study the physiological mechanisms of inflammation and the effect of drugs and nutrition on the immune response. Although in vivo lipopolysaccharide (LPS) challenges have been applied as methodological tool in clinical pharmacology studies, detailed information is desired on dose-response relationships, especially regarding LPS hyporesponsiveness observed after low-dose in vivo LPS administration. A randomized, double- blind, placebo-controlled study was performed with single ascending low doses of LPS (0.5-2 ng/kg body weight) to assess the in vivo inflammatory effects of low intravenous LPS doses, and to explore the duration of the induced LPS hyporesponsiveness assessed by subsequent ex vivo LPS challenges in healthy volunteers. The in vivo inflammatory response showed a dose- dependent increase in body temperature, heart rate, CRP and circulating cytokines (TNF-α, IL-1β, IL-6, IL-8) which showed clearly distinctive increases from placebo already at the lowest LPS dose level tested (p≤0.0001). Ex vivo LPS challenges were performed to estimate the duration and magnitude of LPS hyporesponsiveness by assessment of cytokine release. In vivo LPS administration dose-dependently induced a period of hyporesponsiveness in the ex vivo LPS-induced cytokine release, with maximal hyporesponsiveness observed at 6 hours, lasting no longer than 12 hours. For IL-6 and IL-8, indications for immune cell priming were observed. This study expands the knowledge about the dose-effect relationship of LPS-induced hyporesponsiveness. As such, the low-dose LPS challenge has been demonstrated to be a feasible methodological tool for future clinical studies exploring robust pharmacological or subtlenutritional immune-modulating effects.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical and Cellular Immunology.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical and Cellular Immunology
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Marlous Dillingh”